2-Phenyl-2-imidazoline is a heterocyclic compound that has been studied for its potential pharmacological activity. It is a derivative of imidazoline, a class of compounds known for their effects on the cardiovascular system. The synthesis of 2-phenyl-2-imidazoline involves the reaction of benzaldehyde with ethylenediamine under acidic conditions. This compound has been investigated for its ability to act as an alpha-2 adrenergic receptor agonist, which could have implications for treating conditions like hypertension and anxiety. Research has also explored its potential as an anti-inflammatory agent. The compound's importance lies in its potential therapeutic applications and its ability to provide insight into the biological activity of imidazoline derivatives. Further studies are needed to fully understand its pharmacological profile and explore its potential therapeutic value.'
| ID Source | ID |
|---|---|
| PubMed CID | 13639 |
| CHEMBL ID | 274548 |
| SCHEMBL ID | 105024 |
| MeSH ID | M0158486 |
| Synonym |
|---|
| 5-23-06-00425 (beilstein handbook reference) |
| ec 213-313-4 |
| EN300-29510 |
| brn 0119250 |
| 1h-imidazole, 4,5-dihydro-2-phenyl- |
| nsc 54747 |
| einecs 213-313-4 |
| 1h-imidazole,5-dihydro-2-phenyl- |
| nsc54747 |
| 2-phenylimidazoline |
| 2-phenyl-2-imidazoline |
| 2-imidazoline, 2-phenyl- |
| nsc-54747 |
| 936-49-2 |
| 2-phenyl-4,5-dihydro-1h-imidazole |
| STK367860 |
| 2-phenyl-2-imidazoline, >=96% (hplc) |
| AC-11337 |
| bdbm50240363 |
| CHEMBL274548 , |
| P0685 |
| AKOS001429412 |
| F1995-0381 |
| 4,5-dihydro-2-phenyl-1h-imidazole |
| SCHEMBL105024 |
| DTXSID5061322 |
| 4,5-dihydro-2-phenylimidazole |
| W-100236 |
| 2-phenyl-4,5-dihydro-1h-imidazole # |
| 2-phenyl-4,5-dihydroimidazole |
| mfcd00005180 |
| D78018 |
| 2-phenyl imidazoline |
| FT-0762475 |
| Q63392122 |
| 2-imidazoline, 2-phenyl- (6ci,7ci,8ci); 2-phenyl-2-imidazoline |
| STR05026 |
| 2-phenyl-1h-imidazoline |
| CS-0008348 |
| Z283858536 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID392231 | Binding affinity to MAOA imidazoline binding site in rat brain mitochondrial homogenate assessed as 4-hydroxyquinoline production by spectrophotometry | 2009 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2 | Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. |
| AID392232 | Binding affinity to MAOB imidazoline binding site in rat brain mitochondrial homogenate assessed as 4-hydroxyquinoline production by spectrophotometry | 2009 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2 | Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. |
| AID392233 | Selectivity index, ratio of Ki rat for MAOA to Ki for rat MAOB | 2009 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2 | Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. |
| AID91715 | Binding affinity for imidazoline receptor I-2 in rabbit kidney homogenate (relative to [3H]-Idazoxan radioligand) | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | 3D-QSAR CoMFA study on imidazolinergic I(2) ligands: a significant model through a combined exploration of structural diversity and methodology. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.59) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||